Saruparib

Saruparib

Chemical structure of Saruparib

Saruparib is a pharmaceutical drug that belongs to the class of PARP inhibitors. It is primarily used in the treatment of certain types of cancer, particularly those associated with BRCA mutations. Saruparib works by inhibiting the enzyme poly ADP ribose polymerase (PARP), which plays a crucial role in the repair of DNA damage in cells. By blocking this enzyme, Saruparib induces synthetic lethality in cancer cells that are already deficient in homologous recombination repair, leading to cell death.

Mechanism of Action

Saruparib targets the PARP enzyme, which is involved in the repair of single-strand breaks in DNA. In normal cells, PARP helps to repair these breaks, but in cancer cells with defective BRCA1 or BRCA2 genes, the repair process is compromised. Saruparib exploits this vulnerability by further inhibiting PARP, leading to the accumulation of DNA damage and ultimately causing cell death through apoptosis. This mechanism is particularly effective in tumors with BRCA mutations, as these cells rely heavily on PARP for DNA repair.

Clinical Use

Saruparib is used in the treatment of ovarian cancer, breast cancer, and other cancers associated with BRCA mutations. It is often prescribed for patients who have undergone previous treatments and have shown resistance to other forms of chemotherapy. The drug is administered orally and is part of a class of targeted therapies that aim to minimize damage to normal cells while effectively targeting cancer cells.

Side Effects

Common side effects of Saruparib include nausea, fatigue, anemia, and thrombocytopenia. Patients may also experience gastrointestinal disturbances such as diarrhea and vomiting. It is important for patients to be monitored regularly for hematological toxicity and other adverse effects during treatment.

Research and Development

Saruparib is the result of extensive research into PARP inhibitors and their potential in cancer therapy. Ongoing clinical trials are exploring its efficacy in combination with other anticancer agents and its potential use in a broader range of cancers. Researchers are also investigating biomarkers that could predict patient response to Saruparib, aiming to personalize treatment plans and improve outcomes.

Related Pages

• PARP inhibitor
• BRCA mutation
• Ovarian cancer
• Breast cancer
• Targeted therapy